Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.
Company Details
- Employees
- 82
- Founded
- 2022
- Address
- Boston, Massachusetts, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.rapportrx.com
- HQ
- Boston, Massachusetts
Rapport Therapeutics Questions
Rapport Therapeutics's website is http://www.rapportrx.com
Rapport Therapeutics's LinkedIn profile is https://www.linkedin.com/company/rapport-therapeutics
Rapport Therapeutics has
82 employees.
View email and phone details for 82
employees at Rapport Therapeutics.
Rapport Therapeutics's industry is
Biotechnology Research
Rapport Therapeutics's top competitors are
Fable Therapeutics,
Nuvalent, Inc.,
Dyno Therapeutics,
Kalvista Pharmaceuticals, Inc.,
Myrobalan Therapeutics,
Delphia Therapeutics,
Nvelop Therapeutics,
Quiver Bioscience,
Seaport Therapeutics,
Tessera Therapeutics.
Rapport Therapeutics's categories are Biotechnology Research
Rapport Therapeutics's founding year is 2022
